Letter to the EditorImproved asthma outcomes with a simple inhaler technique intervention by community pharmacists
References (8)
- et al.
A scale for the measurement of quality of life in adults with asthma
J Clin Epidemiol
(1992) - et al.
Perceived control of asthma and quality of life among adults with asthma
Ann Allergy Asthma Immunol
(2002) - et al.
Problems with inhaler use: a call for improved clinician and patient education
Respir Care
(2005) - et al.
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability
Eur Respir J
(2002)
Cited by (171)
GEMA 5.3. Spanish Guideline on the Management of Asthma
2023, Open Respiratory ArchivesRecognizing and Tackling Inhaler Technique Decay in Asthma and Chronic Obstructive Pulmonary Disesase (COPD) Clinical Practice
2023, Journal of Allergy and Clinical Immunology: In PracticeIncorrect use of inhalation systems in asthmatic children
2023, Journal de Pediatrie et de PuericultureEffectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study (CONNECT1)
2022, Journal of Allergy and Clinical Immunology: In PracticeThe impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: A systematic review
2022, Respiratory MedicineCitation Excerpt :In view of the demonstrated associations between inhaler misuse, poor asthma outcomes and their contribution to the economic burden of asthma, concerted efforts to check and reinforce good inhaler technique are crucial. Previous studies have shown that training leads to better inhaler technique together with improved asthma control [6,52,65,66], and significant cost savings [65]. Improving patients’ inhaler knowledge and skills requires prescribers knowing how to use different devices correctly and in them choosing the most appropriate device to suit individual patient needs [3].
Rethinking the gold standard – The feasibility of randomized controlled trials within health services effectiveness research
2022, Research in Social and Administrative Pharmacy
Disclosure of potential conflict of interest: H. K. Reddel has consulting arrangements with GlaxoSmithKline and AstraZeneca; has received grant support from GlaxoSmithKline and AstraZeneca; and is on the speakers' bureau for GlaxoSmithKline and AstraZeneca. C. L. Armour has received grant support from the National Health and Medical Research Council of Australia and the Commonwealth Department of Health. The rest of the authors have declared that they have no conflict of interest.